Merck signs up to $3.3 billion cancer drug deal with China-based LaNova
Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months after a ...
Amgen stock falls as analysts mull over weight loss drug's bone density data
Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...
Structure Therapeutics, Inc.: Promising Advances in Metabolic Treatments Drive Buy Recommendation
BMO Capital analyst Evan Seigerman has reiterated their bullish stance on GPCR stock, giving a Buy rating on November 5. Evan Seigerman has ...
MM&M7d
Post-election prescription: Why Trump’s return could disrupt pharma
From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...
Schrodinger’s Promising Growth Potential Highlighted by Novartis Partnership and Strong Fundamentals
In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a ...
BioSpace8d
Gilead Beats Q3 Expectations Fueled by HIV Drug Sales, Raises Full-Year Guidance
BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...
Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...
FiercePharma9d
Trump won a second term. What does it mean for biopharma?
On Tuesday night, millions of Americans watched as former president Donald J. Trump gathered up enough electoral votes needed ...
BioSpace11d
Viking Touts Promising Phase I Weight Loss Data for Obesity Pill Candidate
Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy ...
Shares in weight-loss drugmaker Eli Lilly fall on disappointing sales
Weight-loss drugmaker Eli Lilly delivered lower sales and earnings per share than expected in the third quarter, blaming high ...
Amgen posts higher profit, obesity data on track for late this year
Amgen reported a higher quarterly profit on Wednesday, driven by a 24% rise in sales of drugs for high cholesterol and ...
Regeneron Shares Drop as Higher-Dose Eylea Drug Misses Sales Estimates
The higher-dose version of the eye disease drug was launched in August 2023 and allows for longer intervals between injections for patients. Regeneron's total revenue of $3.72 billion beat ...